Skip to main content
. Author manuscript; available in PMC: 2010 Jul 23.
Published in final edited form as: Vaccine. 2009 Feb 24;27(32):4363–4369. doi: 10.1016/j.vaccine.2009.02.041

Figure 3. Characterization of the in vivo luciferase expression in pcDNA3-luciferase vaccinated mice pre-treated with or without DAC.

Figure 3

C57BL/6 mice (5 per group) were administered 0, 0.25 or 1.0 mg/kg body weight of DAC on days 0, 3 and 7. On the last day of administration of DAC, the mice were administered pcDNA3-luciferase intradermally via gene gun. 24 hours later, the mice were analyzed for luciferase activity using the IVIS Imaging System. Bar graphs depicting the levels of luciferase activity in the different groups of mice are shown. Note: we found a linear trend in the dose effect with a p-value of 0.0397.